Meeting
2019 ASCO Annual Meeting
Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.
Authors
E. Antonio Chiocca
Brigham and Women's Hospital, Boston, MA
E. Antonio Chiocca , Rimas Vincas Lukas , Ganesh Rao , John A. Barrett , Jill Y. Buck , Nathan Demars , Amy Smith , John Miao , Qiang (John) Zhou , Arnold Bruce Gelb , Laurence Cooper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03636477
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2020)
DOI
10.1200/JCO.2019.37.15_suppl.2020
Abstract #
2020
Poster Bd #
209
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.
First Author: E. Antonio Chiocca
Poster
2016 ASCO Annual Meeting
Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.
First Author: Francois M. Lebel
Poster
2014 ASCO Annual Meeting
Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
First Author: John Howard Sampson
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma.
First Author: Richard Francis Dunne